Table 2.
Major clinical trials of OV combination therapy.
| Start time | OVs | Combination drugs | Cancer type | Purpose of the study | Phase | Status | Clinical trial number |
|---|---|---|---|---|---|---|---|
| 2017 | Pexa-Vec | IT ipilimumab (anti-CTLA4 Ab) | Metastatic tumor, advanced tumor | Feasibility, safety and anti-tumor effects after combination therapy | I | Completed | NCT02977156 |
| 2021 | OVV-01 | pembrolizumab (anti-PD-1 monoclonal antibody) or atezolizumab | Neoplasms | Evaluation of safety, tolerability, and efficacy after combination therapy | I | Recruiting | NCT04787003 |
| 2019 | OH2 | HX008 (an anti-PD-1 antibody) | Gastrointestinal cancer, solid tumor | Evaluation of safety and efficacy after combination therapy | I/II | Recruiting | NCT03866525 |
| 2021 | RT-01 | Nivolumab (ICIs) | Advanced solid tumor | Evaluation of safety, tolerability and preliminary efficacy after combination therapy | I | Current recruitment status is unknown | NCT05122572 |
| 2012 | CGTG-102 | low-dose oral cyclophosphamide | Malignant solid tumor | Safety and recommended dose after combination therapy | I | Completed | NCT01598129 |
| 2013 | DNX 2401 | TMZ | Recurrent tumor, glioblastoma multiforme | Evaluation of safety, tolerability, and toxicity after combination therapy | I | Completed | NCT01956734 |
| 2017 | Pexa-Vec (JX-594) | Tremelimumab | Colorectal neoplasms, colorectal cancer, refractory cancer | Evaluation of safety, tolerability and feasibility after combination therapy | I/II | Completed | NCT03206073 |
| 2022 | H101 | Camrelizumab (PD-1 inhibitors) | Bladder cancer | Safety and efficacy assessment after combination therapy | II | Recruiting | NCT05564897 |
| 2020 | CAdVEC | HER2 specific CAR-T cells | Advanced HER2 positive solid tumors | Safety and efficacy assessment after receiving specific T cells after intratumoral CAdVEC injection | I | Recruiting | NCT03740256 |
| 2023 | H101 | PD-1 inhibitors | Advanced malignant pleural mesothelioma | The efficacy and safety of patients with malignant pleural mesothelioma resistant to advanced PD-1 inhibitors after combination therapy | Observational | Recruiting | NCT06031636 |
| 2012 | GL-ONC 1 | CDDP (radiation therapy and cisplatin) | Cancer of head and neck | Safety and tolerability after combination therapy | I | Completed | NCT01584284 |
| 2024 | TILT-123 | Pembrolizumab | Locally advanced, unresectable, refractory and/or metastatic solid tumors | Safety, tolerability, and preliminary antitumor efficacy after combination therapy | I/II | Recruiting | NCT06265025 |
| 2020 | LOAd 703 | Atezolizumab | Malignant melanoma | Evaluation of safety and efficacy after combination therapy | I/II | Completed | NCT04123470 |
| HF10 | Ipilimumab | Malignant melanoma | Whether combination therapy is effective in patients with stage IIIB, IIIC, or stage IV unresectable or metastatic melanoma | II | Completed | NCT02272855 | |
| 2006 | MV-NIS | Cyclophosphamide | Recurrent plasma cell myeloma, refractory plasma cell myeloma | Side effects and optimal dose after combination therapy | I/II | Completed | NCT00450814 |
| 2017 | NIS | Cyclophosphamide, Ipilimumab and nivolumab or cemiplimab | Multiple myeloma, acute myeloid leukemia and T-cell lymphoma | Optimal dose and side effects after combination therapy | I | Recruiting | NCT03017820 |
MV-NIS, oncolytic measles virus encoding thyroidal sodium iodide symporter; NIS, VSV-hIFNbeta-sodium iodide symporter; Pexa-Vec, pexastimogene devacirepvec; TMZ, Temozolomide; HER2, human epidermal growth factor receptor.